FDA panel says no to Alkermes depression pill

Nov 02, 2018

An advisory panel to the U.S. FDA voted against approving Alkermes’ treatment for depression in patients with an inadequate response to standard antidepressant therapies.

The panel voted 21-2 against the drug, ALKS 5461, a once-daily pill combining samidorphan and buprenorphine, developed as an add-on treatment for major depressive disorder.

FDA staff reviewers flagged abuse potential for the opioid-based treatment and raised questions on its efficacy.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments